SwedenBIO：2026年瑞典药物发现与开发研发管线报告（英文版）-三个皮匠报告

1、The Swedish Drug Discovery and Development Pipeline 2026The Swedish pharmaceutical pipeline 2026 consists of 518 projects.Approximately half of the projects are in discovery or preclinical stages and half in clinical phase I-III.A total of 152 pharma and biotech companies headquartered in Sweden are

2、 currently developing new drugs.98 of these(64%)have projects in clinical trials.Highlights since 2023 include 11 approved drugs,over$1.1 billion generated through acquisitions,and a robust portfolio of more than 200 assets currently available for partnering.518 Projects152 CompaniesHighlightsWelcom

3、e to JoinSwedish Life ScienceThis report tells a compelling story of a nation driven by curiosity,a passion for science,entrepreneurial spirit,and openness to the world.It is this ingrained mindset that has shaped Sweden into a leading life science nation.Overall,the Swedish life science industry co

4、ntinues its strong performance.This is evident not only in export statistics but also in the breadth and depth of the Swedish drug development pipeline.Strategic initiatives are underway to further strengthen the sector in areas where there is room for improvement.The Governments Office for Life Sci

5、ences,which coordinates efforts across three ministries in close collaboration with the industry,plays a key role in turning ambition into measurable progress.In 2024,the government adopted an updated national life science strategy,which clearly identifies priority areas for development to maintain

6、and enhance Swedens global position.Clinical trials are one such priority,and joint efforts between public and private stakeholders are now underway to substantially improve the conditions for conducting trials in Sweden.NATIONAL FOREWORDSwedens ambition is to be strong across the entire life scienc

SwedenBIO：2026年瑞典药物发现与开发研发管线报告（英文版）（25页）.pdf

相关报告